Sodium selenate is an inorganic selenite compound that has emerged as a promising disease-modifying therapeutic for tauopathies, including Alzheimer's disease, [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear- palsy) (PSP), and Corticobasal Syndrome (CBS). The compound works primarily by activating Protein Phosphatase 2A (PP2A), the major serine/threonine phosphatase responsible for dephosphorylating tau protein in the brain^1.
Sodium selenate's primary mechanism involves the activation of PP2A, which is the predominant phosphatase responsible for removing phosphate groups from tau at pathologically relevant sites. In Alzheimer's disease and related tauopathies, PP2A activity is reduced by approximately 50%, contributing to tau hyperphosphorylation and neurofibrillary tangle formation^2.
The compound promotes PP2A activation through multiple pathways:
Stabilization of PP2A holoenzyme: Sodium selenate promotes the assembly and stabilization of the PP2A-B55α holoenzyme, the specific form responsible for tau dephosphorylation in the brain^1
Enhancement of methylation: The compound increases Leu309 methylation of the PP2A catalytic subunit, which is essential for B55α regulatory subunit recruitment and holoenzyme assembly^3
Reduction of endogenous inhibitors: Sodium selenate reduces the activity of endogenous PP2A inhibitors such as SET/I2PP2A and CIP2A, which are elevated in AD brain^2
By activating PP2A, sodium selenate facilitates the dephosphorylation of tau at multiple pathologically relevant sites:
This broad dephosphorylation profile distinguishes sodium selenate from kinase inhibitors that typically target individual phosphorylation enzymes^1.
Multiple preclinical studies have demonstrated sodium selenate's efficacy in tauopathy models:
3xTg-AD mice: Sodium selenate treatment reduced tau hyperphosphorylation in the hippocampus and cortex, with improvements in cognitive performance on behavioral tests^1
P301L tau transgenic mice: Treatment with sodium selenate reduced tau pathology and improved synaptic function^4
Mechanism validation: Studies confirmed that the anti-tau effects were PP2A-dependent, as PP2A inhibitors blocked the therapeutic benefit^1
A significant challenge in sodium selenate development has been achieving sufficient brain penetration. Early formulations had limited central nervous system exposure, necessitating high doses that increased the risk of off-target effects. Development programs have focused on improving brain penetration through optimized formulations^5.
The most advanced clinical program (VEL015) evaluated sodium selenate in mild-to-moderate Alzheimer's disease:
Phase IIa results: The trial demonstrated safety and tolerability with biomarker trends suggesting disease modification^3
Primary endpoints: The study met its safety objectives, with trends toward biomarker improvement in cerebrospinal fluid tau levels^5
Status: Further clinical development has continued with a focus on optimizing dosing and formulation
Sodium selenate has been specifically studied in PSP, a 4R-tauopathy where PP2A dysfunction contributes to the characteristic tau pathology:
Rationale: PSP involves predominant 4R-tau aggregation, and PP2A activity is reduced in basal ganglia and brainstem regions affected in PSP^2
Clinical trials: Several Phase 1/2 trials evaluated sodium selenate in PSP patients, with mixed results regarding efficacy^6
Outcome: The PSP trials demonstrated safety but showed limited efficacy in clinical endpoints, leading to reevaluation of the therapeutic approach
The clinical development of sodium selenate has faced significant challenges:
Limited brain penetration: Early formulations did not achieve sufficient CNS exposure, potentially limiting therapeutic efficacy^5
Modest efficacy signals: Clinical trials in both AD and PSP showed biomarker trends but did not meet primary clinical endpoints^3
Formulation challenges: The requirement for intravenous administration limits convenience and long-term use
Narrow therapeutic window: Selenium compounds can be toxic at higher doses, necessitating careful dose selection^6
Mechanism questions: Whether PP2A activation alone is sufficient to modify disease progression remains uncertain
Competition: Other PP2A-targeting approaches (FTY720/fingolimod, SET inhibitors) are in development and may offer advantages^2
Several factors may explain the limited clinical success:
| Compound | Mechanism | Development Stage | Route |
|---|---|---|---|
| Sodium selenate | PP2A activation | Phase 2 | IV/oral |
| FTY720 (fingolimod) | SET inhibition | Preclinical/Phase 1 | Oral |
| AIT-101 (Bixati) | LCMT1 modulation | Phase 1 | Oral |